Phase IIb Study of the Efficacy of FLU-v, a Broad Spectrum Influenza Vaccine in an H1N1 Influenza Healthy Human Challenge Model
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs FLU-v (Primary) ; Montanide ISA-51
- Indications Influenza virus infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors SEEK
- 10 Jan 2019 Primary endpoint has been met. (Incidence of MMID), according to a hVIVO media release.
- 10 Jan 2019 Results presented in a hVIVO media release.
- 06 Jun 2017 Status changed from recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History